Edition:
United States

Analyst Research

Report Title Price
Provider : ValuEngine, Inc.
$25.00
Provider : Stock Traders Daily
$20.00
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Emergent BioSolutions Inc gives Q3 2014 revenue guidance in line with analysts' estimates; raises FY 2014 revenue guidance; reaffirms FY 2014 net income guidance


Thursday, 7 Aug 2014 04:04pm EDT 

Emergent BioSolutions Inc:Increases FY 2014 total revenue forecast to $425 to $450 million, from $415 to $445 million.Anticipates Q3 2014 total revenue of $110 to $125 million.Reaffirms its guidance for FY 2014 adjusted net income of $40 to $50 million and GAAP net income of $30 to $40 million.Q3 2014 revenue of $125 million - Thomson Reuters I/B/E/S.FY 2014 revenue of $432 million and net income of $44 million - Thomson Reuters I/B/E/S.